$USPH
U S PHYSICAL THERAPY INC /NV

2020 Q3 Form 10-Q Financial Statement

#000114036120024780 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3
Revenue $106.9M $117.3M
YoY Change -8.81% 3.65%
Cost Of Revenue $78.50M $89.90M
YoY Change -12.68% 3.21%
Gross Profit $30.36M $27.37M
YoY Change 10.91% 4.97%
Gross Profit Margin 28.39% 23.34%
Selling, General & Admin $10.40M $10.56M
YoY Change -1.48% -0.82%
% of Gross Profit 34.26% 38.56%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $2.740M $2.420M
YoY Change 13.22% -2.02%
% of Gross Profit 9.03% 8.84%
Operating Expenses $10.40M $10.56M
YoY Change -1.48% -0.82%
Operating Profit $19.96M $16.82M
YoY Change 18.68% 8.96%
Interest Expense -$300.0K $557.0K
YoY Change -153.86% -3.8%
% of Operating Profit -1.5% 3.31%
Other Income/Expense, Net
YoY Change
Pretax Income $20.04M $16.27M
YoY Change 23.21% 9.39%
Income Tax $4.300M $3.197M
% Of Pretax Income 21.45% 19.65%
Net Earnings $10.92M $9.047M
YoY Change 20.66% 11.66%
Net Earnings / Revenue 10.21% 7.72%
Basic Earnings Per Share $0.61
Diluted Earnings Per Share $0.61 $703.1K
COMMON SHARES
Basic Shares Outstanding 12.85M 12.77M
Diluted Shares Outstanding 12.85M

Balance Sheet

Concept 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.10M $27.90M
YoY Change 7.89% -13.35%
Cash & Equivalents $30.10M $27.86M
Short-Term Investments
Other Short-Term Assets $3.200M $7.098M
YoY Change -54.92% 44.86%
Inventory
Prepaid Expenses
Receivables $49.30M $47.12M
Other Receivables $0.00 $0.00
Total Short-Term Assets $82.60M $92.53M
YoY Change -10.74% 2.02%
LONG-TERM ASSETS
Property, Plant & Equipment $100.3M $21.37M
YoY Change 369.31% 6.86%
Goodwill $336.9M $316.6M
YoY Change 6.41%
Intangibles $54.06M $53.39M
YoY Change 1.26%
Long-Term Investments
YoY Change
Other Assets $1.500M $1.470M
YoY Change 2.04% 5.0%
Total Long-Term Assets $492.8M $468.3M
YoY Change 5.24% 28.55%
TOTAL ASSETS
Total Short-Term Assets $82.60M $92.53M
Total Long-Term Assets $492.8M $468.3M
Total Assets $575.4M $560.8M
YoY Change 2.6% 23.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $2.900M
YoY Change -62.07% 38.1%
Accrued Expenses $60.24M $33.57M
YoY Change 79.42% -16.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.999M $718.0K
YoY Change 596.24% -85.04%
Total Short-Term Liabilities $93.20M $62.80M
YoY Change 48.41% 33.61%
LONG-TERM LIABILITIES
Long-Term Debt $7.509M $55.29M
YoY Change -86.42% 1.08%
Other Long-Term Liabilities $60.50M $718.0K
YoY Change 8326.18% -73.41%
Total Long-Term Liabilities $7.509M $56.01M
YoY Change -86.59% -2.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $93.20M $62.80M
Total Long-Term Liabilities $7.509M $56.01M
Total Liabilities $310.5M $188.1M
YoY Change 65.1% -22.64%
SHAREHOLDERS EQUITY
Retained Earnings $181.1M
YoY Change
Common Stock $150.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.63M
YoY Change
Treasury Stock Shares $2.215M
Shareholders Equity $264.9M $235.5M
YoY Change
Total Liabilities & Shareholders Equity $575.4M $565.2M
YoY Change 1.81% 24.22%

Cashflow Statement

Concept 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $10.92M $9.047M
YoY Change 20.66% 11.66%
Depreciation, Depletion And Amortization $2.740M $2.420M
YoY Change 13.22% -2.02%
Cash From Operating Activities $26.24M $17.84M
YoY Change 47.09% -23.73%
INVESTING ACTIVITIES
Capital Expenditures -$860.0K -$2.550M
YoY Change -66.27% 25.0%
Acquisitions
YoY Change
Other Investing Activities -$3.970M -$4.170M
YoY Change -4.8% -42.16%
Cash From Investing Activities -$4.840M -$6.730M
YoY Change -28.08% -27.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -34.84M -18.12M
YoY Change 92.27% 100.22%
NET CHANGE
Cash From Operating Activities 26.24M 17.84M
Cash From Investing Activities -4.840M -6.730M
Cash From Financing Activities -34.84M -18.12M
Net Change In Cash -13.44M -7.010M
YoY Change 91.73% -237.72%
FREE CASH FLOW
Cash From Operating Activities $26.24M $17.84M
Capital Expenditures -$860.0K -$2.550M
Free Cash Flow $27.10M $20.39M
YoY Change 32.91% -19.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000885978
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q3 usph Average Physical Therapy Patients Volumes Per Day Per Clinic
AveragePhysicalTherapyPatientsVolumesPerDayPerClinic
25.8
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
9047000
CY2020Q3 usph Cash Received Related To Sale Of Clinics
CashReceivedRelatedToSaleOfClinics
700000
CY2020Q3 usph Note Receivable Related To Sale Of Clinics
NoteReceivableRelatedToSaleOfClinics
400000
usph Number Of Installments For Note Receivable In Sale Consideration
NumberOfInstallmentsForNoteReceivableInSaleConsideration
2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q3 usph Number Of Clinics Operated
NumberOfClinicsOperated
550
usph Percentage Of General Partnership Interest Owned
PercentageOfGeneralPartnershipInterestOwned
0.01
CY2020Q3 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
39
usph Number Of Third Party Facilities
NumberOfThirdPartyFacilities
38
CY2020Q3 usph Deferment Depositing Of Employer Share Social Security Taxes
DefermentDepositingOfEmployerShareSocialSecurityTaxes
4900000
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1900000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2020Q1 usph Average Physical Therapy Patients Volumes Per Day Per Clinic
AveragePhysicalTherapyPatientsVolumesPerDayPerClinic
26.2
CY2020Q2 usph Average Physical Therapy Patients Volumes Per Day Per Clinic
AveragePhysicalTherapyPatientsVolumesPerDayPerClinic
18.9
CY2020Q1 usph Percentage Of Employees Furloughed Or Terminated
PercentageOfEmployeesFurloughedOrTerminated
0.40
CY2020Q1 dei Entity Number Of Employees
EntityNumberOfEmployees
5500
CY2020Q2 usph Number Of Furloughed Employees Returned
NumberOfFurloughedEmployeesReturned
1200
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Reduction In Combined Physical Therapy Speech Language Pathology Expenses
ReductionInCombinedPhysicalTherapySpeechLanguagePathologyExpenses
3000
CY2020Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
108929000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
117251000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
305503000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
359855000
usph Estimated Percentage Of Decrease In Payment
EstimatedPercentageOfDecreaseInPayment
0.09
usph Period Of Federal Debt Ceiling In Connection With Deficit Reductions
PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions
P10Y
usph Amount Of Reductions In Federal Spending
AmountOfReductionsInFederalSpending
1200000000000
usph Reduction In Medicare Spending Percentage
ReductionInMedicareSpendingPercentage
0.02
CY2013Q2 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2015Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2018Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
usph Percentage Of Payment Adjustment Temporary Suspended
PercentageOfPaymentAdjustmentTemporarySuspended
0.02
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Percentage Of Practice Expense Component Of Relative Value Unit
PercentageOfPracticeExpenseComponentOfRelativeValueUnit
1
usph Percentage Reduction For Service In Office Or Other Non Institutional Settings
PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings
0.50
usph Percentage Of Payment For Outpatient Therapy Services
PercentageOfPaymentForOutpatientTherapyServices
0.85
usph Difference Between Net Revenues And Corresponding Cash Collections Reflected Percentage Of Net Revenues
DifferenceBetweenNetRevenuesAndCorrespondingCashCollectionsReflectedPercentageOfNetRevenues
0.01
usph Difference Between Actual Aggregate Contractual Reserve Percentages As Compared To Estimated Contractual Allowance Reserve Percentage
DifferenceBetweenActualAggregateContractualReservePercentagesAsComparedToEstimatedContractualAllowanceReservePercentage
0.01
usph Maximum Contractual Allowance Reserve Estimate
MaximumContractualAllowanceReserveEstimate
0.01
usph Gain On Sale Of Closed Clinics
GainOnSaleOfClosedClinics
1100000
CY2020Q3 usph Number Of Clinics Closed
NumberOfClinicsClosed
12
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
10916000
us-gaap Net Income Loss
NetIncomeLoss
22164000
CY2019 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
7325000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12774000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12829000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12750000
CY2019Q4 us-gaap Goodwill
Goodwill
317676000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1859000
CY2018Q4 us-gaap Goodwill
Goodwill
293525000
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
1305000
CY2019 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
146000
CY2020Q3 us-gaap Goodwill
Goodwill
336946000
CY2019Q4 us-gaap Goodwill
Goodwill
317676000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1900000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
19824000
CY2019 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
31330000
us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
0
us-gaap Net Income Loss
NetIncomeLoss
32110000
CY2020Q3 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-4298000
CY2019Q3 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-922000
usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
1175000
usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-10752000
usph Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRate
0.2625
CY2020Q3 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-1228000
CY2019Q3 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-242000
usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
308000
usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-2822000
CY2020Q3 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
7846000
CY2019Q3 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
8367000
usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
23031000
usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
24180000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.61
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.66
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.80
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.90
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12847000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
60236000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30855000
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
54060000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
52588000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
834000
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
765000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2547000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2217000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26834000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19340000
CY2020Q3 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
6823000
CY2019Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
4303000
CY2020Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1741000
CY2019Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2277000
CY2020Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1654000
CY2019Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
116000
CY2020Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
3831000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0
CY2020Q3 usph Medicare Accelerated And Advance Payments Program Funds Payable
MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable
12924000
CY2019Q4 usph Medicare Accelerated And Advance Payments Program Funds Payable
MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable
0
CY2020Q3 usph Deferred Employer Payroll Taxes Caresact
DeferredEmployerPayrollTaxesCARESACT
4879000
CY2019Q4 usph Deferred Employer Payroll Taxes Caresact
DeferredEmployerPayrollTaxesCARESACT
0
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1550000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4819000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
12508000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
51089000
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
4999000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
728000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7509000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
50361000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4999000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7509000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
12508000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
7470000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
7708000
us-gaap Operating Lease Cost
OperatingLeaseCost
23097000
us-gaap Operating Lease Cost
OperatingLeaseCost
15295000
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
389000
CY2019Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
297000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
898000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
668000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1436000
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1547000
us-gaap Variable Lease Cost
VariableLeaseCost
4482000
us-gaap Variable Lease Cost
VariableLeaseCost
3128000
CY2020Q3 us-gaap Lease Cost
LeaseCost
9295000
CY2019Q3 us-gaap Lease Cost
LeaseCost
9552000
us-gaap Lease Cost
LeaseCost
28477000
us-gaap Lease Cost
LeaseCost
19091000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
7696000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
7686000
us-gaap Operating Lease Payments
OperatingLeasePayments
22041000
us-gaap Operating Lease Payments
OperatingLeasePayments
15392000
CY2020Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3162000
CY2019Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8629000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22238000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
98514000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7994000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
27451000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
21506000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
15566000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9847000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
10504000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
92868000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5826000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
87042000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.032
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.032
CY2020Q3 us-gaap Revenues
Revenues
108929000
CY2019Q3 us-gaap Revenues
Revenues
117251000
us-gaap Revenues
Revenues
305503000
us-gaap Revenues
Revenues
359855000
CY2020Q3 us-gaap Gross Profit
GrossProfit
30357000
CY2019Q3 us-gaap Gross Profit
GrossProfit
27372000
us-gaap Gross Profit
GrossProfit
65332000
us-gaap Gross Profit
GrossProfit
85515000
CY2020Q3 us-gaap Assets
Assets
575438000
CY2019Q3 us-gaap Assets
Assets
560845000
CY2008Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
2250000
CY2009Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1200000
CY2009Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
859499
usph Additional Estimated Repurchase Of Common Stock
AdditionalEstimatedRepurchaseOfCommonStock
172652
CY2020Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
86.88
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0

Files In Submission

Name View Source Status
0001140361-20-024780-index-headers.html Edgar Link pending
0001140361-20-024780-index.html Edgar Link pending
0001140361-20-024780.txt Edgar Link pending
0001140361-20-024780-xbrl.zip Edgar Link pending
brhc10016616_10q.htm Edgar Link pending
brhc10016616_10q_htm.xml Edgar Link completed
brhc10016616_ex-32.htm Edgar Link pending
brhc10016616_ex31-1.htm Edgar Link pending
brhc10016616_ex31-2.htm Edgar Link pending
brhc10016616_ex31-3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usph-20200930.xsd Edgar Link pending
usph-20200930_cal.xml Edgar Link unprocessable
usph-20200930_def.xml Edgar Link unprocessable
usph-20200930_lab.xml Edgar Link unprocessable
usph-20200930_pre.xml Edgar Link unprocessable